GLP-1 & compounded medication availability in Colorado (2026)

Colorado’s distinctive move is a sworn promise: before an out-of-state pharmacy may register to ship here, it signs an affidavit that compounded medication will only ever arrive against a prescription written for a specific patient. That is the model OrderlyMeds runs on everywhere, so nothing about ordering from Denver or Durango works differently, but the paperwork behind it is worth seeing, and it is cited below from the state’s own rule text.

Baseline state

Availability facts last reviewed: November 16, 2026

What reaches Colorado addresses, line by line

Availability of all ten OrderlyMeds product lines in Colorado, with typical delivery times and notes
Product lineAvailable in Colorado?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Shipped against patient-specific prescriptions, as Colorado’s own rules require.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days One national price per dose; Colorado pays what every state pays.
NAD+ Yes 8–10 business days From partner pharmacies registered with the state as nonresident outlets.
Sermorelin Yes 8–10 business days Same signup flow, same national pricing.
Glutathione No N/A Not something OrderlyMeds offers today.
BPC-157 Yes 8–10 business days Injectable compound; its federal history is spelled out below.
TB-500 Yes 8–10 business days Injectable compound. The cited federal facts sit just under this table.
KPV No N/A Not in the formulary anywhere; we compound peptides as injectables only.
Epitalon Yes 8–10 business days Injectable compound; read its federal entry before ordering.
MOTS-c Yes 8–10 business days Injectable compound whose federal entry differs from the other peptides’.

An honest No beats a padded catalog, so absent lines are shown, not hidden. Colorado rows reviewed November 16, 2026.

Research peptides in Colorado: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Four of these five peptide lines reach Colorado through OrderlyMeds: BPC-157, TB-500, Epitalon and MOTS-c, every one a compounded injectable dispensed against a patient-specific prescription. In Colorado that is more than our own practice. It is the condition in the affidavit every registered nonresident pharmacy signs. KPV does not ship because we compound peptides exclusively as injectables and KPV is not one. Each line’s federal record follows, and they are not interchangeable.

BPC-157 in Colorado

Reaches Colorado as a compounded injectable, patient-specific prescription only. The federal picture:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Colorado

A Colorado-available compounded injectable, dispensed per patient. Federally:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Colorado

Does not ship to Colorado, or any state. Our compounded peptides are injectables; KPV is not among them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Colorado

In the formulary for Colorado as an injectable, prescription written per patient. Its record:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Colorado

Available in Colorado as a compounded injectable on a per-patient prescription. Note how its federal entry departs from the others’:

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

The paperwork Colorado requires before anything compounded crosses its border

Where most states fold compounded-medication shipping into general licensure, Colorado makes the compounding condition explicit at registration time. The two rules below come straight from the pharmacy regulator’s own rulebook (3 CCR 719-1). Together they mean an out-of-state pharmacy serving Colorado has sworn, in writing and in advance, to the exact dispensing model OrderlyMeds uses.

To register, a nonresident prescription drug outlet must give Colorado’s pharmacy regulator an affidavit attesting that it “shall not ship compounded or other prescription drugs into the State of Colorado without a prescription order for a specific patient,” alongside proof of home-state licensure and a recent inspection report. 3 CCR 719-1, Rule 5.00.15. Source: Code of Colorado Regulations, 3 CCR 719-1 (State Board of Pharmacy rules).

Registered nonresident outlets may dispense compounded products and ship them into Colorado only pursuant to valid, patient-specific prescription orders. 3 CCR 719-1, Rule 21.00.20(b). Source: Code of Colorado Regulations, 3 CCR 719-1.

The same rule set contains no semaglutide-, tirzepatide-, GLP-1- or peptide-specific restriction; Colorado’s compounding standards (Rule 21.00.00) govern process and quality generally, incorporating USP requirements. Source: Code of Colorado Regulations, 3 CCR 719-1.

Colorado permits prescribing on the basis of an appropriate telehealth evaluation meeting the state’s standard of care; no in-person-first requirement applies to the medications on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

None of this adds friction for a Colorado patient. The affidavit binds the pharmacy, not you. Your path is the usual one: online eligibility check, evaluation by a Colorado-licensed provider, fulfillment by a registered partner pharmacy, at the same national price shown on our pricing page.

Colorado availability FAQs

Is compounded semaglutide shipped to Colorado?

Yes. Partner pharmacies registered with Colorado as nonresident outlets fill and ship it against your individual prescription. New customers start at $74/month for the first two months.

What is the affidavit Colorado requires?

Before registering, an out-of-state pharmacy swears in writing that compounded medication will only ship into Colorado against a prescription written for a specific patient. The regulator section above quotes and links the rule.

Do BPC-157 or MOTS-c reach Colorado?

Yes, along with TB-500 and Epitalon, as compounded injectables on patient-specific prescriptions. KPV does not ship anywhere; it falls outside our injectable-only peptide formulary.

What’s the delivery window for Colorado?

8–10 business days from signup, the same published window we quote nationally.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone